ArticleBMJ open2022

Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study.

Michihiro Iwaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.